ACU vs LGCY

ACU presents a dichotomy between a rock-solid balance sheet and deteriorating short-term operational momentum. The Piotroski F-Score of 4/9 indicates stable but mediocre financial health, while the absence of an Altman Z-Score is offset by an exceptionally low Debt/Equity ratio (0.24) and a high Current Ratio (4.21). While the stock is fairly valued—trading between its Graham Number ($40.16) and Intrinsic Value ($48.95)—the recent Q/Q EPS collapse of -47.8% and a bearish technical trend (0/100) suggest significant near-term headwinds.

LGCY exhibits strong fundamental health with a Piotroski F-Score of 7/9 and exceptional growth metrics, including 40.7% YoY revenue growth and 50% earnings growth. While the current price of $11.21 is above the conservative Graham Number ($7.02), it remains significantly discounted relative to its growth-based intrinsic value of $17.70. The company maintains a very healthy balance sheet with low debt (D/E 0.34) and high liquidity (Current Ratio 2.98). Despite short-term technical weakness and minor insider selling, the underlying profitability (ROE 20.06%) and valuation relative to sector peers make it an attractive growth play.